NY-AQARA
8.5.2024 09:01:35 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, announced the global availability of its next-generation Matter hub, the Hub M3. Designed with a focus on edge computing, the M3 prioritizes privacy and local automation capabilities that can operate independently of internet connection or even the hub itself1. Thanks to the versatile connectivity built-in, it seamlessly integrates Aqara accessories, infrared-compatible gadgets and a number of third-party Matter devices, making it a central point for smart home automation while ensuring privacy and easy setup.
“Aqara is committed to creating the ultimate smart home experience that continuously adapts to users’ evolving needs,” said Cathy You, Aqara Senior Vice President of Global Business and Strategy. “The Hub M3's edge computing capabilities will provide users with an added layer of stability and safety, while its Matter compatibility will significantly enhance interoperability and choice for users."
Debuted at CES in January, the M3 stands out as an Edge Hub by enabling not only data privacy through end-to-end encrypted, local storage but also advanced, local automation capabilities. For Aqara users who already own an Aqara Zigbee hub, deploying a Hub M3 further strengthens the robustness of their smart home networks. Moreover, it enables more local automations between Aqara devices. Once added to the network, the M3 takes a lead over other Aqara Zigbee hubs and Wi-Fi devices, and allows automation between these devices to execute on the Edge instead of over the cloud, ensures continued functionality during internet or cloud service disruptions2. The Hub M3 also allows select Aqara Zigbee devices with Repeater functionality to act as a proxy hub and execute automations in the absence of M3. Upcoming Aqara Thread devices with Mesh Extender functionality are expected to support device binding via the M3.
As the latest evolution in Aqara’s lineup of smart home control centers, the M3 supports multiple protocols including Thread, Zigbee, Wi-Fi, Bluetooth and infrared (IR), making it a comprehensive hub for smart home management. It connects and manages the lineup of classic Aqara Zigbee devices, serving as a Matter bridge3. Thanks to the 360° IR blaster, the new hub optimizes control of IR-enabled devices by syncing their status directly with Aqara Home whenever an IR remote is utilized. Moreover, the M3 integrates the latest Aqara Thread devices as well as select Matter-compatible devices from third-party brands to Aqara Home4. This means that users can connect and manage devices from different brands and ecosystems within the Aqara Home app to ensure maximum flexibility and compatibility.
Other enhancements of the Hub M3 include:
- Matter bridge for infrared AC units: It can integrate an infrared-compatible air conditioning unit or air-to-air heat pump to Matter, allowing for AC control and automation via Matter-enabled platforms5.
- Seamless group migration: Users can easily migrate bridged device from older Aqara hubs to the M32, ensuring continuity of Aqara Home settings and automations without the need to reconfigure each device.
- Enhanced internet connectivity: The M3 features dual-band Wi-Fi (2.4GHz/5GHz) with WPA3 security as well as a PoE-enabled port, offering enhanced stability and flexibility.
- Powerful speaker: The 95dB speaker built-in can be used for home security alerts and custom announcements.
The Hub M3 is now available at Aqara’s Amazon brand stores throughout North America (US, Canada), Europe (France, Germany, Italy, Poland, Spain, UK) and Asia (Japan), as well as through select Aqara retailers worldwide.
For more information on the M3, please visit our website.
1. Some Aqara Home automation may require Internet and cloud service to function, for example, automations involve push notifications and location services (e.g., geofencing, local weather, sunrise/sunset).
2. Edge automation and group migration are not supported by the original Aqara Hub and Camera Hub G2H.
3. Not all Aqara Zigbee devices can be bridged to Matter.
4. Third-party Matter device support is limited to select brands and device types by the time of M3 launch.
5. The functionality of infrared AC units may vary depending on each particular Matter-enabled platform. Each M3 hub can bridge one infrared AC unit to Matter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508489885/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom